Postmarketing adverse drug reactions
A duty to report?
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published July 19, 2013.
Article Versions
- Previous version (July 19, 2013 - 13:30).
- You are viewing the most recent version of this article.
Author Disclosures
- Eran Klein, MD, PhD and
- Dennis Bourdette, MD
- Eran Klein, MD, PhD and
1. NIMH DSMB member
NONE
1. AAN speaker honorarium
NONE
NONE
1. Story of Bioethics, Georgetown University Press, 2003.
NONE
NONE
NONE
NONE
NONE
NONE
1. Veterans Affairs, Geriatric Neurology fellowship, fellow, 2010-2011
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Dennis Bourdette, MD
NONE
NONE
I have received honoraria for speaking from Biogen Idec and Teva Neurosciences.
Journal of Medicinal Medicine, Associate Editor, 2009- present ; Current Neurology and Neuroscience Reports, Section Editor, 2008-2011; Autoimmune Diseases, Associate Editor, 2009-present; Neurology, Member Editorial Board, 2013- present. I receive no compensation for any of these activities.
I have a use patent pending for the treatment of multiple sclerosis with cyclic peptide derivatives of cyclosporin.
NONE
NONE
I have served as a consultant to Elan Corporation in the past 12 months.
I am a member of the Biogen Idec speaker's bureau.
I have received support for patient and physician education programs from Teva Neuroscience, Biogen Idec, EMD Serono and Novartis.
NONE
NONE
1. NIH/NINDS, 1R01NS057433, PI,4/1/08-3/31/13 2. Department of Veterans Affairs/BLR&D, Merit Review, PI, 10/1/09-9/30/13
NONE
National MS Society, CA 1055-A-3, PI, 4/1/08-3/31/13
NONE
NONE
NONE
NONE
NONE
NONE
- Department of Neurology (EK, DB), Oregon Health & Science University; Neurology Service (EK, DB), Department of Veterans Affairs Medical Center; and MS Center of Excellence–West (DB), Department of Veterans Affairs Medical Center, Portland, OR.
- Correspondence to:
kleine{at}ohsu.edu
Article usage
The Nerve!: Rapid online correspondence
- LETTER RE: Postmarketing adverse drug reactions: A duty to report?
- Khichar Shubhakaran, Dr. S. N. Medical College, Jodhpur, India, drkhicharsk@gmail.com
- ; Rekha Jakur Khichar; Dr. S. N. Medical College, Jodhpur, India
Submitted June 21, 2014 - AUTHORS RESPOND: Postmarketing adverse drug reactions: A duty to report?
- Eran Klein, Oregon Health & Science University, and Neurology Service, Department of Veterans Affairs Medical Ce, kleine@ohsu.edu
- ; Dennis Bourdette, Oregon Health & Science University, Neurology Service, Department of Veterans Affairs Medical Center, and MS Center of Excellence-West, Department of Veterans Affairs Medical Center, Portland
Submitted June 21, 2014
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.